Abstract
The phase I trial in breast cancer conducted by Peters et al. defined a regimen of high-dose chemotherapy consisting of cyclophosphamide, cisplatinum and BCNU (CPA/cDDP/BCNU). In chemotherapy-resistant metastatic disease, 23% of patients achieved complete remission followed by early relapse. In a phase II study, 53% of stage IV patients with no prior treatment achieved complete response (CR) with 16% progression-free at five to nine years post-transplant. Chemically debulking with an Adriamycin, 5FU, and Methotrexate regimen (AFM) to minimal tumor burden achieved 68% CR, with approximately 20% disease-free patients at 36 months. Other high dose chemotherapy regimens have been developed, again demonstrating in stage IV patients complete remissions in excess of 65% and progression-free survival rates of 20-30%.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary*
-
Bone Neoplasms / therapy
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology*
-
Carmustine / administration & dosage
-
Cisplatin / administration & dosage
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Hematopoietic Stem Cell Transplantation / methods*
-
Humans
-
Methotrexate / administration & dosage
-
Neoplasm Staging
-
Remission Induction
-
Transplantation, Autologous
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Alkylating
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Fluorouracil
-
Carmustine
-
Methotrexate